Endonovo Therapeutics(OTC) ENDV

Endonovo Therapeutics, Inc. is a biotechnology company focused on developing non-invasive electroceutical medical devices for regenerative medicine. The primary product, SofPulse, aims to provide therapeutic relief for various medical conditions, including chronic wounds and post-operative pain.

Products and Services

• SofPulse: Advanced non-invasive therapeutic device
• Applications for soft tissue injuries and chronic wounds
• Technology for managing central nervous system disorders

Growth Outlook

• Expanding applications in cardiovascular and kidney disorders
• Potential market growth in regenerative medicine sector
• Increased interest in non-invasive treatment options

Financial Highlights

• Recent quarterly net income of -$588,365
• Trailing twelve months (TTM) revenue of $0
• Current liabilities significantly exceed total assets

Endonovo Therapeutics, Inc. operates in a niche market with a focus on innovative medical technology. The company's flagship product, SofPulse, is designed to address a variety of medical conditions, which positions it well within the growing field of regenerative medicine. The increasing demand for non-invasive treatment options may provide significant opportunities for future growth. Financially, the company has faced challenges, as indicated by the recent quarterly net income loss and the absence of revenue over the trailing twelve months. The current liabilities substantially exceed total assets, highlighting the need for strategic financial management. Despite these challenges, the potential for market expansion in regenerative medicine and the unique applications of its technology may attract investor interest.